CN106995446B - 布鲁顿酪氨酸激酶抑制剂制备方法 - Google Patents
布鲁顿酪氨酸激酶抑制剂制备方法 Download PDFInfo
- Publication number
- CN106995446B CN106995446B CN201610045393.7A CN201610045393A CN106995446B CN 106995446 B CN106995446 B CN 106995446B CN 201610045393 A CN201610045393 A CN 201610045393A CN 106995446 B CN106995446 B CN 106995446B
- Authority
- CN
- China
- Prior art keywords
- preparation
- reaction solvent
- ethyl acetate
- reaction
- phenoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610045393.7A CN106995446B (zh) | 2016-01-22 | 2016-01-22 | 布鲁顿酪氨酸激酶抑制剂制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610045393.7A CN106995446B (zh) | 2016-01-22 | 2016-01-22 | 布鲁顿酪氨酸激酶抑制剂制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106995446A CN106995446A (zh) | 2017-08-01 |
CN106995446B true CN106995446B (zh) | 2021-07-02 |
Family
ID=59428396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610045393.7A Active CN106995446B (zh) | 2016-01-22 | 2016-01-22 | 布鲁顿酪氨酸激酶抑制剂制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106995446B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111116593B (zh) * | 2019-11-27 | 2020-11-24 | 河北合佳医药科技集团股份有限公司 | 一种连续的伊鲁替尼的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101674834A (zh) * | 2007-03-28 | 2010-03-17 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton’s tyrosine kinase)抑制剂 |
CN102656173A (zh) * | 2009-10-12 | 2012-09-05 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂 |
CN102887900A (zh) * | 2006-09-22 | 2013-01-23 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
CN104844609A (zh) * | 2015-05-12 | 2015-08-19 | 杭州和正医药有限公司 | 双位点不可逆布鲁顿酪氨酸激酶抑制剂 |
US20150307500A1 (en) * | 2007-12-27 | 2015-10-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
-
2016
- 2016-01-22 CN CN201610045393.7A patent/CN106995446B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102887900A (zh) * | 2006-09-22 | 2013-01-23 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
CN101674834A (zh) * | 2007-03-28 | 2010-03-17 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton’s tyrosine kinase)抑制剂 |
US20150307500A1 (en) * | 2007-12-27 | 2015-10-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CN102656173A (zh) * | 2009-10-12 | 2012-09-05 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂 |
CN104844609A (zh) * | 2015-05-12 | 2015-08-19 | 杭州和正医药有限公司 | 双位点不可逆布鲁顿酪氨酸激酶抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN106995446A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6347396B2 (ja) | 新規な複素環含有アミノ酸化合物及びその用途 | |
CN111170892B (zh) | 一种n-甲基(2s)-2-n-芴甲氧羰基氨基-门冬氨酸(4-叔丁酯)的合成方法 | |
CN107474107B (zh) | Glyx-13的制备方法及用于制备glyx-13的化合物 | |
CN101426795B (zh) | 制备多佐胺的方法 | |
CN111646998B (zh) | 一种伊布替尼的合成方法 | |
CN106459150A (zh) | 合成五肽的制造方法 | |
CN106995446B (zh) | 布鲁顿酪氨酸激酶抑制剂制备方法 | |
CN105712919A (zh) | 酰胺缩合剂在维格列汀合成方法中的应用 | |
CN108623602B (zh) | 一种制备和纯化依鲁替尼的方法 | |
CN104530006B (zh) | 兰索拉唑的制备方法 | |
CN111116587A (zh) | 一种阿维巴坦中间体化合物的制备方法 | |
CN106883227B (zh) | 通过麦角菌发酵废料制备麦角新碱的方法 | |
CN112939814B (zh) | 一种氘代达卡他韦中间体的制备方法 | |
CN103539832B (zh) | 一种硼替佐米工艺的改进方法 | |
CN108558890A (zh) | 一种西地那非中间体合成方法 | |
EP2643308B1 (en) | Process for the preparation of taurolidine and its intermediates thereof | |
CN104530112A (zh) | 依维莫司中间体及其乙基化杂质的制备方法 | |
CN104016954A (zh) | 奈必洛尔中间体的制备及纯化方法 | |
CN107216332A (zh) | 叔丁基‑7‑羟甲基‑7,8‑二氢4h吡唑并二氮杂卓5(6h)甲酸基酯的合成方法 | |
CN110015978B (zh) | O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法 | |
JP2019505487A (ja) | 長鎖化合物の製造方法 | |
CN113185552A (zh) | 一种富马酸丙酚替诺福韦降解杂质的制备方法 | |
CN113278021A (zh) | 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法 | |
CN106928149A (zh) | 一种奥拉帕尼的制备方法 | |
CN111116593A (zh) | 一种连续的、低成本的伊鲁替尼的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of Bruton tyrosine kinase inhibitor Effective date of registration: 20211224 Granted publication date: 20210702 Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016193 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221028 Granted publication date: 20210702 Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016193 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of Bruton tyrosine kinase inhibitor Effective date of registration: 20221103 Granted publication date: 20210702 Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980020531 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |